OpenAI acquires Orchestra Bio to expand its life sciences AI work
OpenAI has acquired Orchestra Bio, a startup developing AI agents for drug development. OpenAI plans to add the startup’s team and technology to Rosalind, its AI model for life sciences research, and Rosalind Workbench, a tool for planning experiments and analyzing results. The deal brings Orchestra Bio’s technology into OpenAI’s efforts to support pharmaceutical and biopharma research and drug development.